See more : Lookers plc (LOOK.L) Income Statement Analysis – Financial Results
Complete financial analysis of CG Oncology, Inc. Common stock (CGON) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CG Oncology, Inc. Common stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Citic Press Corporation (300788.SZ) Income Statement Analysis – Financial Results
- Trinity Place Holdings Inc. (TPHS) Income Statement Analysis – Financial Results
- Racing Force S.P.A. (ALRFG.PA) Income Statement Analysis – Financial Results
- Guanhao Biotech Co.,Ltd. (300238.SZ) Income Statement Analysis – Financial Results
- BioCube, Inc. (BICB) Income Statement Analysis – Financial Results
CG Oncology, Inc. Common stock (CGON)
Industry: Biotechnology
Sector: Healthcare
About CG Oncology, Inc. Common stock
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 204.00K | 191.00K | 10.36M |
| Cost of Revenue | 0.00 | 15.00K | 10.00K |
| Gross Profit | 204.00K | 176.00K | 10.35M |
| Gross Profit Ratio | 100.00% | 92.15% | 99.90% |
| Research & Development | 45.75M | 29.03M | 18.32M |
| General & Administrative | 9.90M | 6.41M | 4.65M |
| Selling & Marketing | 0.00 | -15.00K | -10.00K |
| SG&A | 9.90M | 6.39M | 4.64M |
| Other Expenses | 0.00 | -196.00K | 218.00K |
| Operating Expenses | 55.65M | 35.42M | 22.95M |
| Cost & Expenses | 55.65M | 35.44M | 22.96M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.00K | 451.00K |
| Depreciation & Amortization | 17.00K | 15.00K | 10.00K |
| EBITDA | -55.43M | -35.23M | -12.38M |
| EBITDA Ratio | -27,172.55% | -18,445.55% | -121.61% |
| Operating Income | -55.45M | -35.25M | -12.61M |
| Operating Income Ratio | -27,180.88% | -18,453.40% | -121.70% |
| Total Other Income/Expenses | 6.84M | -197.00K | -233.00K |
| Income Before Tax | -48.61M | -35.44M | -12.84M |
| Income Before Tax Ratio | -23,826.96% | -18,556.54% | -123.95% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 |
| Net Income | -48.61M | -35.44M | -12.84M |
| Net Income Ratio | -23,826.96% | -18,556.54% | -123.95% |
| EPS | -15.65 | -0.53 | -0.19 |
| EPS Diluted | -15.65 | -0.53 | -0.19 |
| Weighted Avg Shares Out | 4.33M | 66.64M | 66.64M |
| Weighted Avg Shares Out (Dil) | 4.33M | 66.64M | 66.64M |
CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
CG Oncology, Inc. achieved positive results from its phase 3 BOND-003 study using cretostimogene for the treatment of high-risk BCG unresponsive NMIBC patients; Final data expected end of 2024.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT - IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE)...
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, will host a virtual investor event on...
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that an abstract with final...
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session - - New 12-month data from the Phase 3 BOND-003 trial to be...
How to Find Up-and-Coming Stocks to Buy Right Now
One way to find potentially winning stocks to buy in March, April, and throughout the year is to search for companies gaining more attention from Wall Street analysts.
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
Biotech businesses tend to be volatile after their initial public offerings. Kyverna Therapeutics raised more than twice what was initially expected.
IPO freeze gives way to cautious optimism as dealmakers see signs of a thaw
Private-equity and venture-capital firms flourished during the low-interest rate period that followed the 2008 financial crisis with a brisk pace of mergers and acquisitions, as well as a healthy pipeline of initial public offerings.
3 attractive stocks that insiders are buying
The insiders are buying these attractive stocks. With a bank, a tech, a penny stock, a dividend payer, and a pharmaceutical winner, there is something for all.
Insider Buying at These Biotechs Is Huge
As January wound to a close, the most notable insider purchases were in biopharma companies, particularly those with initial or secondary offerings of stock.
Source: https://incomestatements.info
Category: Stock Reports